Intuitive Surgical Q1 2026 Earnings Beat Estimates

Intuitive Surgical’s Q1 2026 earnings, reported on April 21 (ISRG), exceeded expectations, prompting a modest increase in the company’s full-year procedure-growth forecast while executives warned of potential margin pressures in the second half.

Quarter Results and Outlook

The company announced first-quarter revenue of $2.77 billion, a 23% increase year over year, with recurring revenue accounting for $2.4 billion or 86% of sales. Non-GAAP diluted earnings per share reached $2.50, while GAAP net income was $822 million, or $2.28 per diluted share. These gains reflected higher procedure volumes and operating leverage.

Non-GAAP gross margin expanded to 67.8% from 66.4% a year earlier, and non-GAAP operating margin stood at 39%. Management said tariffs and rising oil and memory prices will create gross-margin headwinds in the second half, limiting further expansion.

The company raised its full-year 2026 da Vinci procedure-growth guidance to 13.5%–15.5% from 13%–15%. It projected non-GAAP operating-expense growth of 11%–14%, non-cash stock compensation between $890 million and $920 million, other income of $315 million to $335 million, and a non-GAAP effective tax rate of 22%–23%. Consensus estimates for the second quarter call for earnings per share of $2.47 on about $2.78 billion in revenue.

Procedure Growth and Revenue Mix

Da Vinci procedures totaled 847,000 in the quarter, up 16% year over year, driven by a 14% increase in the U.S. and 19% growth outside the U.S. Ion procedures rose 39% to 43,000. The guidance increase reflected stronger U.S. general-surgery adoption and growth in non-urology procedures overseas.

The company placed 431 da Vinci systems, a 17% rise from 367 a year earlier. Of these, 232 were da Vinci 5 units, and 56% of placements were through leasing, indicating a shift toward flexible acquisition models. Higher placements supported expansion of the installed base.

Systems revenue grew 24% to $651 million. Instruments and accessories generated $1.7 billion, a 23% increase, with average revenue per procedure rising to $1,880 from $1,780 a year earlier. Service revenue increased 19% to $434 million. This revenue mix, heavily weighted toward consumables and service, continues to drive recurring revenue linked to procedure volumes.

Cash and investments declined to $8 billion from $9 billion. The company acquired a distribution business covering Italy, Spain, and Portugal, adding about 230 employees. This combination of a reduced cash position and targeted regional expansion reflects simultaneous capital returns and organic growth efforts.

The dominance of recurring revenue, rising instrument and accessory sales, and stronger system placements, along with the modest guidance increase, indicate sustained top-line momentum. However, margin upside appears limited in the second half due to elevated expense guidance and cost pressures flagged by management.

"Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion," said Dave Rosa on the earnings call.